Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2025	Dec. 31, 2024
Current Assets:
Cash	$ 390,435	$ 307,442
Restricted cash	79,019	182,284
Prepaid expenses and other current assets	180,015	487,046
Total Current Assets	649,469	976,772
Equipment and furnishings, less accumulated depreciation of $118,617 and $118,151, respectively	4,396	4,863
Operating lease right-of-use asset	12,392	24,624
Total Assets	666,257	1,006,259
Current Liabilities:
Accounts payable	743,968	1,106,551
Unearned grant revenue	57,480	336,108
Other accrued expenses	2,204,338	2,175,376
Notes payable	124,578	206,463
Operating lease liability, current portion	12,729	25,299
Total Current Liabilities	5,735,238	6,975,484
Total Liabilities	5,735,238	6,975,484
Commitments, contingencies, and litigations (Note 13)
Stockholders’ Deficit:
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 420,279,879 shares issued and outstanding at March 31, 2025 and December 31, 2024	420,280	420,280
Additional paid-in capital	253,086,238	251,090,027
Accumulated other comprehensive loss	(60,689)	(60,741)
Accumulated deficit	(258,563,069)	(257,422,961)
Total stockholders’ deficit attributable to Provectus Biopharmaceuticals, Inc., stockholders	(5,102,812)	(5,959,332)
Non-controlling interest	33,831	(9,893)
Total Stockholders’ Deficit	(5,068,981)	(5,969,225)
Total Liabilities and Stockholders’ Deficit	666,257	1,006,259
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock,value	957	957
Series D-1 Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock,value	13,471	13,106
Nonrelated Party [Member]
Current Liabilities:
Accrued interest	30,533	27,774
Convertible notes payable	700,000	853,000
Related Party [Member]
Current Liabilities:
Accrued interest	121,612	144,913
Convertible notes payable	$ 1,740,000	$ 2,100,000